Danish Entertainment Stock News

AGM decisions put capital returns and share structure in focus Dampskibsselskabet Norden (CPSE:DNORD) has drawn fresh attention after its 11 March AGM approved a final 2025 dividend of DKK 2.00 per share and adopted share capital reduction amendments to its Articles of Association. See our latest analysis for Dampskibsselskabet Norden. Those AGM decisions come after a strong run in the share price, with a 90 day share price return of 16.5% and a 1 year total shareholder return of 53.48%. This...

Danske Bank (CPSE:DANSKE) has reversed its long-standing crypto policy, allowing customers to access Bitcoin and Ethereum ETPs. The products are available through the bank's digital platforms and are provided via partnerships with BlackRock and WisdomTree. This is the first time the bank is offering regulated digital asset investment options to its retail clients. The bank maintains a cautious stance on crypto, highlighting the high risk profile of these assets. Danske Bank is Denmark's...

Investors may be wondering whether Genmab at DKK 1,680 is starting to look like value, or if it is still pricing in a lot of optimism. The stock is up 22.0% over the past year, even though the year-to-date return is a 16.3% decline after 7 day and 30 day returns of 4.4% and 10.2% declines. Recent attention on Genmab has centered on its position in the pharmaceuticals and biotech space and how investors are weighing its long-term potential against near-term price volatility. This mix of...

Ørsted (CPSE:ORSTED) has proposed the election of three new board members at its annual general meeting scheduled for April 2026. The nominees are Karen Boesen, Karl Johnny Hersvik, and Samuel Leupold, each bringing experience in energy and renewables. Two current board members are not seeking re election, which would reshape the composition of Ørsted's board if the proposals are approved. For shareholders, these board changes come with Ørsted's share price at DKK144.0 and a mixed return...

What NKT’s latest debt moves could mean for shareholders NKT (CPSE:NKT) has launched a tender offer for its outstanding callable subordinated capital securities and plans to issue new €150 million green callable subordinated capital securities alongside €150 million 5.00% callable notes. For you as an equity investor, these steps point to active balance sheet management, with refinancing and a clearer capital structure at the center, while also tying part of NKT’s funding directly to green...

Novo Nordisk (CPSE:NOVO B) released phase 2 data for its triple agonist obesity drug UBT251, targeting GLP-1, GIP and glucagon receptors. The trial reported significant weight loss in participants, adding a new contender to the GLP-1 class of obesity treatments. This update arrives as competition in obesity drugs intensifies, with Eli Lilly, Structure Therapeutics and others pursuing rival therapies. Novo Nordisk, trading at DKK241.5, is coming off a weak share price stretch, with the...

A.P. Møller - Mærsk (CPSE:MAERSK B) has drawn investor focus after suspending several Middle East linked services for security reasons, while alliances like Gemini and Torus Defence Supply Chain are reshaping its global logistics role. See our latest analysis for A.P. Møller - Mærsk. Recent events such as the temporary suspension of Middle East services, the Gemini cooperation improving schedule reliability for large retailers, the Torus Defence Supply Chain alliance in the UK, and the new...

H. Lundbeck (CPSE:HLUN B) has reached a key clinical milestone, announcing that the final patient has been randomized in its global Phase 3 MASCOT trial for amlenetug in multiple system atrophy, earlier than anticipated. See our latest analysis for H. Lundbeck. Despite this milestone and recent moves such as appointing a Chief AI Officer and presenting at the AD/PD 2026 conference, H. Lundbeck’s 30 day share price return of a 2.97% decline and year to date share price return of an 11.91%...

Why Coloplast’s CEO transition is in focus Coloplast (CPSE:COLO B) is back on investors’ radar after the board appointed Gavin Wood as President and CEO, effective 1 May 2026, following a year under interim chief Lars Rasmussen. Wood arrives from senior roles at Johnson & Johnson MedTech EMEA and previous leadership positions at Mölnlycke and Ethicon, raising questions about how his background could shape Coloplast’s future direction and its healthcare portfolio. See our latest analysis for...

Recent price performance and business mix GN Store Nord (CPSE:GN) has attracted attention after a 0.2% one day move and double digit gains over the past week, contrasting with weaker returns over the past year and past 3 months. For readers trying to put this swing into context, it helps to look at the current financial snapshot and how the business is split across its core segments and regions. GN Store Nord reports annual revenue of DKK 16,782 and net income of DKK 653, supported by three...

Lundbeck’s plan to share new Phase 1b data on Lu AF28996 and advances in multiple system atrophy research, including the partnered antibody amlenetug, puts Genmab (CPSE:GMAB) back on investors’ radar this week. See our latest analysis for Genmab. Genmab’s latest neurological partnership headlines arrive after a softer patch for the shares, with a 1 month share price return of 9.98% and a year to date share price return of 14.57%. The 1 year total shareholder return of 22.51% contrasts with...

Why Zealand Pharma stock is in focus after new obesity trial data Zealand Pharma (CPSE:ZEAL) has moved into the spotlight after announcing that its investigational obesity therapy petrelintide met the primary endpoint in a large Phase 2 trial, showing statistically significant weight loss versus placebo. See our latest analysis for Zealand Pharma. The positive petrelintide data arrives after a difficult period for Zealand Pharma shareholders. A 30 day share price return of 29.15% and a 90 day...

With no specific news event driving Ringkjøbing Landbobank (CPSE:RILBA) today, the stock’s recent performance and valuation metrics offer a starting point for assessing whether its current DKK 1,508 price looks appealing. See our latest analysis for Ringkjøbing Landbobank. The recent dip in Ringkjøbing Landbobank’s 1 month share price return of 7.94% contrasts with its 1 year total shareholder return of 23.33%, which may suggest cooling momentum after a strong multi year run supported by a...

Ørsted (CPSE:ORSTED) just reached a key project milestone as the Revolution Wind joint venture began feeding electricity into New England’s grid, backed by fixed-price, 20-year contracts with utilities in Rhode Island and Connecticut. See our latest analysis for Ørsted. The latest progress at Revolution Wind comes as Ørsted’s share price, now at DKK149.05, has a 90 day share price return of 9.6% and a year to date share price return of 16.45%. However, the 1 year total shareholder return is...

For investors wondering whether Bavarian Nordic at DKK181.55 is a bargain or already pricing in its prospects, this article walks through the key numbers that may matter. The share price has recorded a 0.2% decline over the past week and is down 5.4% over the last month, while still showing a 9.3% gain over the past year. Recent coverage around Bavarian Nordic has focused on its position within the wider pharmaceuticals and biotech space, giving investors more context on how its pipeline and...

Københavns Lufthavne (CPSE:KBHL) has wrapped up FY 2025 with Q4 revenue of DKK 1,368 million and basic EPS of DKK 32.95, while trailing twelve month figures sit at DKK 5.5 billion in revenue and EPS of DKK 158.00, reflecting earnings growth of 19.6% over the period. The company has seen quarterly revenue move from DKK 1,245 million and EPS of DKK 24.98 in Q4 2024 to DKK 1,368 million and EPS of DKK 32.95 in Q4 2025, with margins stepping up from 20% to 22%. This puts profitability at the...

Earlier this month, Zealand Pharma reported positive topline Phase 2 ZUPREME-1 results showing petrelintide achieved statistically significant, clinically meaningful weight loss with tolerability similar to placebo in people living with overweight and obesity. The data suggest petrelintide’s once-weekly amylin-based profile could offer a differentiated, potentially more tolerable alternative to existing peptide weight-loss therapies, reinforcing Zealand’s obesity franchise with Roche. We’ll...

Bank of England contract puts ISS (CPSE:ISS) in focus ISS (CPSE:ISS) has attracted fresh investor attention after announcing a new 4 year integrated facilities services contract, with a 1 year extension option, with the Bank of England across multiple UK sites. See our latest analysis for ISS. The Bank of England win comes as ISS shares trade at DKK217.0, with a 16.6% decline in the 1 month share price return contrasting with a 34.33% 1 year total shareholder return, suggesting longer term...

A.P. Møller - Mærsk has formed a new UK defence supply chain alliance with Amentum, GXO Logistics and Accenture. The partnership focuses on defence readiness and supply chain resilience for mission critical government operations. The move extends Maersk's integrated logistics offering into higher security, technology driven contracts in the defence sector. A.P. Møller - Mærsk (CPSE:MAERSK B) is adding a new leg to its business with this defence focused alliance, alongside its core global...

Earnings event puts Københavns Lufthavne (CPSE:KBHL) in focus Københavns Lufthavne (CPSE:KBHL) just released full year 2025 results, reporting higher sales, revenue, and net income than the prior year. This has put the airport operator’s profitability and recent share performance under closer investor scrutiny. See our latest analysis for Københavns Lufthavne. The earnings release comes after a mixed year in the market, with the share price at DKK6,440 and recent gains such as a 1 day share...

If you are wondering whether TORM's current share price lines up with its underlying worth, you are not alone and this article is built to help you frame that question clearly. The stock last closed at DKK 158.70, after a 14.0% decline over the past week, a 0.6% decline over the last month, but with returns of 26.8% year to date and 45.0% over the past year. These moves have put TORM on the radar for investors who track shipping and tanker companies, and they raise the question of what is...

Evaluating Bavarian Nordic after recent share performance Bavarian Nordic (CPSE:BAVA) has drawn attention after a mixed stretch for the shares, with a 1 day gain of about 2.2% but declines over the past week, month and past 3 months. For investors tracking longer horizons, the stock shows a positive 1 year total return and a modest gain over 3 years. This is set against a weaker 5 year outcome, which naturally raises questions about how the current valuation lines up with fundamentals. See...

Columbus (CPSE:COLUM) has wrapped up FY 2025 with fourth quarter revenue of DKK 385.5 million and basic EPS of DKK 0.05, setting a mixed tone after a year that included both profitable and loss‑making quarters. Over recent periods the company has seen quarterly revenue move from DKK 416.9 million and EPS of DKK 0.23 in Q4 2024, through swings such as Q1 2025 revenue of DKK 434.0 million with EPS of DKK 0.20 and Q2 2025 revenue of DKK 409.9 million with a loss per share of DKK 0.06, before...

If you are wondering whether Novo Nordisk's current share price really reflects its underlying worth, you are not alone. This article is here to walk you through that question step by step. After a strong long term story, the stock is now sitting at DKK 247.05 following a 0.3% decline over the last 7 days, a 19.4% decline over 30 days, a 25.2% decline year to date and a 52.1% decline over the past year, with a 22.2% return over 5 years and a 46.8% return over 3 years. Recent headlines around...